Biological Psychiatry
May 15, 2011
Noemí Santana, Eva Troyano-Rodriguez, Guadalupe Mengod et al.
Noncompetitive N-methyl-D-aspartate receptor antagonists are widely used as pharmacological models of schizophrenia. Their neurobiological actions are still poorly understood, although the prefrontal cortex (PFC) appears as a key target area. We examined the effect of phencyclidine (PCP) on neuronal activity of the mediodorsal (MD) and centromedial (CM) thalamic nuclei, reciprocally connected...
Biological Psychiatry
May 6, 2011
Amy K. Ricke, R. Snook, A. Anand
34 citations
Ms. M is a 42-year-old Caucasian married woman with a history of chronic left gluteal and left leg pain diagnosed as reflex sympathetic dystrophy. She was disabled by refractory symptoms that had failed a number of interventions and required high-dose opioids. Ms. M was otherwise high functioning and had completed a professional degree. The patient elected to undergo experimental IV ketamine...
Biological Psychiatry
February 3, 2011
Nanxin Li, Rong-Jian Liu, J. Dwyer et al.
Background Despite widely reported clinical and preclinical studies of rapid antidepressant actions of glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonists, there has been very little work examining the effects of these drugs in stress models of depression that require chronic administration of antidepressants, or the molecular mechanisms that could account for the rapid responses....
Biological Psychiatry
2011
Hannah L. Morgan, D. Turner, Philip R. Corlett et al.
Background Our sense of body ownership is profound and familiar, yet it may be misleading. In the rubber-hand illusion, synchronous tactile and visual stimulation lead to the experience that a rubber hand is actually one's own. This illusion is stronger in schizophrenia. Given the evidence that ketamine, a noncompetitive N-methyl-D-aspartate antagonist reproduces symptoms of schizophrenia, we...
Biological Psychiatry
January 1, 2011
Yanhui Liao, Jinsong Tang, Philip R. Corlett et al.
Use of ketamine as a recreational drug is spreading rapidly among young people all over the world. Epidemiological studies have linked chronic ketamine use with a number of problems, including cognitive impairments, bladder dysfunction, and ketamine-related death. However, little is known about the long-term effects of ketamine use on brain structure and function. We used voxel based...
Biological Psychiatry
December 4, 2010
Michael Kometer, B. Rael Cahn, David Andel et al.
101 citations
BackgroundRecent findings suggest that the serotonergic system and particularly the 5-HT2A/1A receptors are implicated in visual processing and possibly the pathophysiology of visual disturbances including hallucinations in schizophrenia and Parkinson's disease.MethodsTo investigate the role of 5-HT2A/1A receptors in visual processing the effect of the hallucinogenic 5-HT2A/1A agonist...
Biological Psychiatry
December 1, 2010
Is ecstasy an empathogen?
Biological Psychiatry
October 14, 2010
Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.
Biological Psychiatry
April 10, 2010
Philip R. Corlett, D. D’Souza, J. Krystal
We would like to report a case of Capgras syndrome in a healthy subject, which was induced by ketamine, [an antagonist of the N-methyl D-aspartate (NMDA) subtype of glutamate receptors]. We believe this is the first report of delusion-like misidentification following controlled administration of a psychotomimetic drug, raising the possibility that the neurochemical and cognitive mechanisms...
Biological Psychiatry
January 15, 2010
Marije Aan Het Rot, Katherine A. Collins, James W. Murrough et al.
A single subanesthetic (intravenous) IV dose of ketamine might have rapid but transient antidepressant effects in patients with treatment-resistant depression (TRD). Here we tested the tolerability, safety, and efficacy of repeated-dose open-label IV ketamine (six infusions over 12 days) in 10 medication-free symptomatic patients with TRD who had previously shown a meaningful antidepressant...
Biological Psychiatry
October 15, 2009
Yvette I. Sheline, Marcus E. Raichle, Abraham Z. Snyder et al.
608 citations
BackgroundImportant functional connections within the default mode network (DMN) are disrupted in Alzheimer's disease (AD), likely from amyloid-beta (Abeta) plaque-associated neuronal toxicity. Here, we sought to determine if pathological effects of Abeta amyloid plaques could be seen, even in the absence of a task, by examining functional connectivity in cognitively normal participants with...
Biological Psychiatry
July 9, 2009
R. Price, Matthew K. Nock, D. Charney et al.
Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between two concepts, may have utility in suicide assessment. Methods Twenty-six patients with treatment-resistant depression were...
Biological Psychiatry
February 15, 2009
Giacomo Salvadore, Brian R Cornwell, Veronica Colon-Rosario et al.
Most patients with major depressive disorder (MDD) experience a period of lengthy trial and error when trying to find optimal antidepressant treatment; identifying biomarkers that could predict response to antidepressant treatment would be of enormous benefit. We tested the hypothesis that pretreatment anterior cingulate cortex (ACC) activity could be a putative biomarker of rapid...
Biological Psychiatry
December 1, 2008
Stefan Borgwardt, Paul Allen, Sagnik Bhattacharyya et al.
This study examined the effect of Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on brain activation during a motor inhibition task. Functional magnetic resonance imaging and behavioural measures were recorded while 15 healthy volunteers performed a Go/No-Go task following administration of either THC or CBD or placebo in a double-blind, pseudo-randomized, placebo-controlled repeated...
Biological Psychiatry
November 8, 2008
Laura E. Phelps, Nancy E. Brutsché, J. Moral et al.
Background A high rate of comorbidity exists between mood disorders and alcohol dependence. Furthermore, both ketamine, a dissociative anesthetic with a recently described rapid-onset antidepressant effect, and ethanol are N-methyl-D-aspartate (NMDA) receptor antagonists. Previous investigations of healthy individuals with a family history of alcohol-dependence have found that these individuals...
Biological Psychiatry
June 1, 2008
Clara Touriño, Catherine Ledent, Rafaël Maldonado et al.
3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug widely abused by young people. The endocannabinoid system is involved in the addictive processes induced by different drugs of abuse. However, the role of this system in the pharmacological effects of MDMA has not yet been clarified. Locomotion, body temperature, and anxiogenic-like responses were evaluated after acute MDMA...
Biological Psychiatry
February 15, 2008
Sungho Maeng, Carlos A. Zarate, Jing Du et al.
Ketamine exerts a robust, rapid, and relatively sustained antidepressant effect in patients with major depression. Understanding the mechanisms underlying the intriguing effects of N-methyl d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action. The learned helplessness, forced swim, and passive avoidance tests were used to investigate ketamine's behavioral...
Biological Psychiatry
February 1, 2008
Daniela Braida, Valeria Limonta, Valeria Capurro et al.
107 citations
The recreational drug, Salvinorin A, derived from the plant of Salvia divinorum, is a potent and selective kappa-opioid receptor agonist. The abuse of selective k-agonists is a novel phenomenon, the mechanism of which is not fully understood. We investigated salvinorin A given SC on the conditioned place preference (.05-160 microg/kg) and intracerebroventricular (ICV) self-administration (.01-1...
Biological Psychiatry
January 15, 2008
Keith A Trujillo, Juan J Zamora, Kathleen P Warmoth
Ketamine has been used for many years as a dissociative anesthetic; however, there is evidence of increasing abuse, especially at dance clubs and raves. In addition, there is increasing interest in the use of subanesthetic doses of ketamine for the treatment of pain and depression, as well as for clinical research on schizophrenia. Despite growing use, relatively little is known about the...
Biological Psychiatry
January 1, 2008
Svetlana Semenova, Mark A. Geyer, J Gregor Sutcliffe et al.
Studies have implicated the serotonin (5-HT)(7) receptor in physiological and pathophysiological phenomena, including thermoregulation, central control of micturition and locomotion, regulation of circadian rhythm, sleep, and depression. Further, several antidepressant and antipsychotic drugs have high affinity for the 5-HT(7) receptor. We examined the role of 5-HT(7) receptors in a rodent...
Biological Psychiatry
September 15, 2007
Mauro Federici, Luca Sebastianelli, Silvia Natoli et al.
Although dopamine (DA) has been implicated in the psychostimulant properties of 3,4-methylenedioxymethamphetamine (MDMA), there is no detailed information on its modalities of action on single ventral midbrain dopaminergic neurons. We examined the actions of MDMA on intracellularly recorded dopaminergic neurons maintained in slices. At 1 micromol/L, MDMA depolarized and excited the cells; at 3...
Biological Psychiatry
June 1, 2007
Derik Hermann, Alexander Sartorius, Helga Welzel et al.
Cannabinoids present neurotoxic and neuroprotective properties in in vitro studies, inconsistent alterations in human neuroimaging studies, neuropsychological deficits, and an increased risk for psychotic episodes. Proton magnetic resonance spectroscopy ((1)H-MRS), neuropsychological testing, and hair analysis for cannabinoids was performed in 13 male nontreatment-seeking recreational cannabis...
Biological Psychiatry
April 15, 2006
Dan Rujescu, Andreas Bender, Martin Keck et al.
The psychotomimetic effects of N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) in healthy humans and their ability to exacerbate psychotic symptoms in schizophrenic patients have promoted a view of schizophrenia as being related to altered glutamatergic neurotransmission. This prompted us and others to develop animal models for psychosis based on a glutamatergic...
Biological Psychiatry
October 15, 2005
John H. Halpern, Andrea R Sherwood, James I. Hudson et al.
186 citations
Hallucinogens are widely used, both by drug abusers and by peoples of traditional cultures who ingest these substances for religious or healing purposes. However, the long-term residual psychological and cognitive effects of hallucinogens remain poorly understood. We recruited three groups of Navajo Native Americans, age 18-45: 1) 61 Native American Church members who regularly ingested peyote,...
Biological Psychiatry
March 15, 2005
Deepak Cyril D'Souza, Walid Michel Abi-Saab, Steven Madonick et al.
Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders. In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated...